Case Report: Retransplantation Due to Hepatocellular Carcinoma After Direct Antiviral Agents in Cirrhotic Patients
https://doi.org/10.52420/umj.23.6.80
EDN: XHLRAV
Abstract
Introduction. Direct antiviral agents had opened new opportunities of treatment for chronic hepatitis C (HCV) in patients with cirrhosis. However, patients with decompensated liver cirrhosis need special attention and individual approach before antiviral therapy prescription.
The aim of the study — to demonstrate a clinical case probability of developing liver cirrhosis complications aſter effective antiviral therapy.
Materials and methods. Analysis of medical records of 52 уears old male with HCV-associated liver cirrhosis who was treated with direct antiviral agents with achieving of sustained virologic response (SVR). During follow up hepatocellular carcinoma (HCC) was detected. Patient underwent a liver transplantation complicated by primary non function liver graſt in the early postoperative period. Liver retransplantation with necessity of extracorporeal treatment methods and complex immunosuppressive therapy.
Discussion. Antiviral treatment of patients with decompensated liver cirrhosis does not always improve prognosis and sustained SVR does not exclude risk of HCC appearance.
Conclusion. Treated patients should be included in monitoring and HCC surveillance program.
About the Authors
M. A. Anashkina
Sverdlovsk Regional Clinical Hospital No. 1
Russian Federation
Competing Interests:
Russian Federation
Maria A. Anashkina — Gastroenterologist of the Gastroenterology Department, Sverdlovsk Regional
Hepatological Center
Ekaterinburg
Competing Interests:
The authors declare the absence of obvious or potential conflict of interest.
E. N. Bessonova
Sverdlovsk Regional Clinical Hospital No. 1; Ural State Medical University; Ministry of Health of the Sverdlovsk Region
Russian Federation
Competing Interests:
Russian Federation
Elena N. Bessonova — Doctor of Sciences (Medicine), Head of the Gastroenterology Department, Head of the Sverdlovsk Regional Hepatological Center, Sverdlovsk Regional Clinical Hospital No. 1; Associate Professor of the Department of Polyclinic Therapy, Ural State Medical University; Chief Freelance Specialist in Gastroenterologist, Ministry of Health of the Sverdlovsk Region
Ekaterinburg
Competing Interests:
The authors declare the absence of obvious or potential conflict of interest.
N. F. Klimusheva
Sverdlovsk Regional Clinical Hospital No. 1; Ural State Medical University
Russian Federation
Competing Interests:
Russian Federation
Nataliya F. Klimusheva — Doctor of Sciences (Medicine), Deputy Director for Medical Work, Sverdlovsk Regional Clinical Hospital No. 1; Associate Professor of the Department of Urology, Nephrology and Transplantation, Ural State Medical University
Ekaterinburg
Competing Interests:
The authors declare the absence of obvious or potential conflict of interest.
References
1. Pimenov NN, Komarova SV, Karandashova IV, Tsapkova NN, Volchkova EV, Chulanov VP. Hepatitis С and its outcomes in Russia: Analysis of incidence, prevalence and mortality rates before the start of the program of infection elimination. Infectious Diseases. 2018;16(3):37–45. (In Russ.). DOI: https://doi.org/10.20953/1729-9225-2018-3-37-45.
2. Chen CJ, Huang YH, Hsu CW, Chen YC, Chang ML, Lin CY, et al. Hepatitis C micro-elimination through the retrieval strategy of patients lost to follow-up. BMC Gastroenterology. 2023;23:40. DOI: https://doi.org/10.1186/s12876-023-02665-y.
3. Sharma SA, Kowgier M, Hansen BE, Brouwer WP, Maan R, Wong D, et al. Toronto HCC risk index: A validated scoring system to predict 10-year risk of HCC in patients with cirrhosis. Journal of Hepatology. 2018;68(1):92–99. DOI: https://doi.org/10.1016/j.jhep.2017.07.033.
4. Ivashkin VT, Chulanov VP, Mamonova NA, Maevskaya MV, Zharkova MS, Tikhonov IN, et al. Clinical practice guidelines of the Russian Society for the Study of the Liver, the Russian Gastroenterological Association, the National Scientific Society of Infectious Disease Specialists for the diagnosis and treatment of chronic hepatitis C. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2023;33(1):84–124. (In Russ.). DOI: https://doi.org/10.22416/1382-4376-2023-33-1-84-124.
5. Lleo A, Aglitti A, Aghemo A, Maisonneuve P, Bruno S, Persico M; collaborators. Predictors of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals. Digestive and Liver Disease. 2019;51(2):310–317. DOI: https://doi.org/10.1016/j.dld.2018.10.014.
6. Nabatchikova E, Zasorina D, Rozina T, Nikulina E, Tanashchuk E, Abdurakhmanov Dzh, et al. Risk stratification of hepatocellular carcinoma in cirrhotic patients aſter hepatitis C virus eradication: Russian single-center experience. Journal of Hepatology. 2022;77(S1):S574–S575. (In Russ.). DOI: https://doi.org/10.1016/S0168-8278(22)01472-6.
7. Cheung MCM, Walker A, Hudson B, Verma S, McLuchlan J, Mutimer D, et al. Outcomes aſter successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis. Journal of Hepatology. 2016;65(4):741–747. DOI: https://doi.org/10.1016/j.jhep.2016.06.019.
8. Fernandez-Carrillo C, Lens S, Llop E, Pascasio JM, Crespo J, Arenas J, et al. Treatment of hepatitis C virus in patients with advanced cirrhosis: Always justified? Analysis of the HEPA-C registry. Hepatology. 2017; 65(6):1810–1822. DOI: https://doi.org/10.1002/hep.29097.
9. Foster GR, McLauchlan J, Irving W, Cheung M, Hudson B, Verma S, et al. Treatment of decompensated HCV cirrhosis in patients with diverse genotypes: 12 weeks sofosbuvir and NS5A inhibitors with/without ribavirin is effective in HCV genotypes 1 and 3. Journal of Hepatology. 2015;62(S2):S190–S191. DOI: https://doi.org/10.1016/S0168-8278(15)30009-X.
10. Chulanov VP, Pimenov NN, Mamonova NA, Sagalova OI, ShestakovaIV, Pokrovsky VI. Chronic hepatitis C in Russia: Current challenges and prospects. Terapevticheskii arkhiv. 2015;87(11):5–10. (In Russ.). DOI: https://doi.org/10.17116/terarkh201587115-10.
11. Thriſt AP, El-Serag HB, Kanwal F. Global epidemiology and burden of HCV infection and HCV-related disease. Nature Reviews Gastroenterology and Hepatology. 2017;14(2):122–132. DOI: https://doi.org/10.1038/nrgastro.2016.176.
12. Chhatwal J, Samur S, Kues B, Ayer T, Roberts MS, Kanwal F, et al. Optimal timing of hepatitis C treatment for patients on the liver transplant waiting list. Hepatology. 2017;65(3):777–788. DOI: https://doi.org/10.1002/hep.28926.
13. Aleman S, Rahbin N, Weiland O, Davidsdottir L, Hedenstierna M, Rose N, et al. A risk for hepatocellular carcinoma persists long-term aſter sustained virologic response in patients with hepatitis C-associated liver cirrhosis. Clinical Infectious Diseases. 2013;57(2):230–236. DOI: https://doi.org/10.1093/cid/cit234.
14. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012; 142(6):1264–1273.e1. DOI: https://doi.org/10.1053/j.gastro.2011.12.061. Erratum in: Gastroenterology. 2012;143(1):269. DOI: https://doi.org/10.1053/j.gastro.2012.06.002.
15. Samant H, Amiri HS, Zibari GB. Addressing the worldwide hepatocellular carcinoma: epidemiology, prevention and management. Journal of Gastrointestinal Oncology. 2021;12(S2):361–373. DOI: https://doi.org/10.21037/jgo.2020.02.08.
16. Galle PR, Forner A, Llovet JM, Mazzaferro V, Piscaglia F, Raoul JL, et al. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. Journal of Hepatology. 2018;69(1):182–236. DOI: https://doi.org/10.1016/j.jhep.2018.03.019. Erratum in: Journal of Hepatology. 2019;70(4):817. DOI: https://doi.org/10.1016/j.jhep.2019.01.020.
17. Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67(1):358–380. DOI: https://doi.org/10.1002/hep.29086.
Supplementary files
Review
For citations:
Anashkina MA, Bessonova EN, Klimusheva NF. Case Report: Retransplantation Due to Hepatocellular Carcinoma After Direct Antiviral Agents in Cirrhotic Patients. Ural Medical Journal. 2024;23(6):80–90. (In Russ.) https://doi.org/10.52420/umj.23.6.80. EDN: XHLRAV
Views:
112
Email this article 